Volume | 3,068 |
|
|||||
News | (1) | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
51.59 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
148 | 3,068 | - | 47.58 - 71.065 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:47:12 | 30 | $ 51.76 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
104.32B | 2.02B | - | 45.01B | 8.03B | 3.97 | 13.00 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 54.44 | 55.035 | 51.53 | 52.47 | 39,410,305 | -2.61 | -4.79% |
1 Month | 49.89 | 55.035 | 49.535 | 52.17 | 20,229,063 | 1.94 | 3.89% |
3 Months | 52.41 | 55.035 | 47.58 | 50.94 | 17,127,427 | -0.58 | -1.11% |
6 Months | 58.56 | 59.46 | 47.58 | 51.83 | 15,265,621 | -6.73 | -11.49% |
1 Year | 66.66 | 71.065 | 47.58 | 56.41 | 12,282,206 | -14.83 | -22.25% |
3 Years | 62.07 | 81.435 | 47.58 | 64.30 | 11,525,142 | -10.24 | -16.50% |
5 Years | 50.01 | 81.435 | 41.19 | 60.76 | 12,430,652 | 1.82 | 3.64% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |